Total amount: € 0,00
HOW TO ORDER
A Journal on Obstetrics and Gynecology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index
Minerva Ginecologica 2013 April;65(2):215-21
The role of oral probiotic for bacterial vaginosis in pregnant women. A pilot study
Facchinetti F. 1, Dante G. 1, Pedretti L. 2, Resasco P. 3, Annessi E. 1, Dodero D. 2 ✉
1 Dipartimento Materno Infantile, Azienda Ospedaliero Universitaria , Policlinico di Modena, Modena, Italia;
2 Unità Operativa di Ginecologia e Ostetricia Ospedale L. Riboli, Lavagna;
3 Dottoressa in Pietistica, libera professionista
Aim: The aim of this study was to compare the effects of a dietary supplementation with oral probiotic, and the treatment with vaginal clindamycin in pregnant women with bacterial vaginosis.
Methods: Fouty pregnant women, with a diagnosis of bacterial vaginosis according to the Amsel criteria, were enrolled between the 10th and the 34th week of gestation. The patients were randomized in two groups. Patients in the group A were treated with probiotic orally (VSL3® Ferring), 2 tablets a day for 5 days, followed by 1 tablet daily for 10 days. Patients in group B were treated with vaginal clindamycin 100 mg daily for 15 days. After 5-10 days from the end of the treatment the patients returned for the follow-up.
Results: After treatment the vaginal discharge was completely absent in group A, and reduced in group B. The itching occurred only in 10% of patients in each of the two groups. The improvement of constipation occurs only in the group A (P=0.002). Vaginal swabs resulted negative in both groups in particular for Gardnerella V.
Conclusion: The oral treatment with VSL#3® is effective in the treatment of VB in pregnant women as a topical treatment with clindamycin. In particular for the resolution of leukorrhea, itching and in particular in the bacterial vaginosis caused by Gardnerella V.